BRPI0416079A - análogos de oligonucleotìdeos de classe c com uma potência imunoestimuladora aumentada - Google Patents

análogos de oligonucleotìdeos de classe c com uma potência imunoestimuladora aumentada

Info

Publication number
BRPI0416079A
BRPI0416079A BRPI0416079-7A BRPI0416079A BRPI0416079A BR PI0416079 A BRPI0416079 A BR PI0416079A BR PI0416079 A BRPI0416079 A BR PI0416079A BR PI0416079 A BRPI0416079 A BR PI0416079A
Authority
BR
Brazil
Prior art keywords
oligonucleotide analogs
inducing
class
oligonucleotides
ifn
Prior art date
Application number
BRPI0416079-7A
Other languages
English (en)
Inventor
Eugen Uhlmann
Joerg Vollmer
Arthur M Krieg
Bernhard O Noll
Original Assignee
Coley Pharm Gmbh
Coley Pharm Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coley Pharm Gmbh, Coley Pharm Group Inc filed Critical Coley Pharm Gmbh
Publication of BRPI0416079A publication Critical patent/BRPI0416079A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"ANáLOGOS DE OLIGONUCLEOTìDEOS DE CLASSE C COM UMA POTêNCIA IMUNOESTIMULADORA AUMENTADA". A invenção se refere a uma classe de oligonucleotídeos imunoestimuladores de CpG contendo um motivo imunoestimulador de CpG e um segundo motivo que é capaz de formar estrutura secundária, incluindo estrutura duplex e de ordem mais elevada, in vitro e in vivo. Os oligonucleotídeos da invenção são úteis como adjuvantes na vacinação. Os oligonucleotídeos são também úteis para a indução de uma resposta imune, indução de expressão de um interferon (IFN) do tipo I, a indução da expressão de interferon gama (IFN-<sym>), e para o tratamento de uma variedade de condições que incluem alergia, asma, infecção e câncer.
BRPI0416079-7A 2003-10-30 2004-10-29 análogos de oligonucleotìdeos de classe c com uma potência imunoestimuladora aumentada BRPI0416079A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51619303P 2003-10-30 2003-10-30
PCT/US2004/036240 WO2005042018A2 (en) 2003-10-30 2004-10-29 C-class oligonucleotide analogs with enhanced immunostimulatory potency

Publications (1)

Publication Number Publication Date
BRPI0416079A true BRPI0416079A (pt) 2007-01-02

Family

ID=34549500

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416079-7A BRPI0416079A (pt) 2003-10-30 2004-10-29 análogos de oligonucleotìdeos de classe c com uma potência imunoestimuladora aumentada

Country Status (23)

Country Link
US (1) US8188254B2 (pt)
EP (2) EP1728863A3 (pt)
JP (1) JP2007509983A (pt)
KR (1) KR101107818B1 (pt)
CN (1) CN101454451A (pt)
AP (1) AP2006003611A0 (pt)
AU (2) AU2004285561C1 (pt)
BR (1) BRPI0416079A (pt)
CA (1) CA2540949A1 (pt)
CR (1) CR8423A (pt)
EA (1) EA008741B1 (pt)
EC (1) ECSP066589A (pt)
GE (1) GEP20094767B (pt)
IL (2) IL174428A0 (pt)
MA (1) MA28182A1 (pt)
NO (1) NO20061857L (pt)
NZ (2) NZ546275A (pt)
OA (1) OA13278A (pt)
SG (2) SG123799A1 (pt)
TN (1) TNSN06123A1 (pt)
UA (1) UA88457C2 (pt)
WO (1) WO2005042018A2 (pt)
ZA (2) ZA200602352B (pt)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
DK1733735T3 (en) 1998-05-22 2017-06-19 Ottawa Hospital Res Inst Methods and products for the induction of mucosal immunity
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
AU4343700A (en) * 1999-04-12 2000-11-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Oligodeoxynucleotide and its use to induce an immune response
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
WO2001097843A2 (en) 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
JP2005500806A (ja) * 2000-09-15 2005-01-13 コーリー ファーマシューティカル ゲーエムベーハー ＣｐＧに基づく免疫アゴニスト／免疫アンタゴニストの高スループットスクリーニングのためのプロセス
EP1404873B1 (en) * 2001-06-21 2013-05-22 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
ES2314099T3 (es) 2001-08-17 2009-03-16 Coley Pharmaceutical Gmbh Oligonucleotidos inmunoestimulantes con motivos combinados con actividad mejorada.
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
CA2480775C (en) 2002-04-04 2016-05-31 Coley Pharmaceutical Gmbh Immunostimulatory g,u-containing oligoribonucleotides
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
CA2503693A1 (en) 2002-10-29 2004-05-13 Coley Pharmaceutical Group, Ltd. Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
JP2006512927A (ja) * 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
RU2351362C2 (ru) 2003-03-26 2009-04-10 Цитос Байотекнолоджи Аг КОНЪЮГАТЫ ПЕПТИДА Melan-A, АНАЛОГА ВИРУСОПОДОБНОЙ ЧАСТИЦЫ
JP2007524615A (ja) 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー 低分子トール様レセプター（ｔｌｒ）アンタゴニスト
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
CN101454451A (zh) 2003-10-30 2009-06-10 科勒制药有限公司 具有增强免疫刺激能力的c类寡核苷酸类似物
US20050100983A1 (en) * 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
CA2567789A1 (en) * 2004-06-08 2006-08-03 Coley Pharmaceutical Gmbh Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
ES2536103T3 (es) 2005-11-25 2015-05-20 Zoetis Belgium S.A. Oligorribonucleótidos inmunoestimuladores
WO2007068747A1 (en) 2005-12-14 2007-06-21 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
PT1991678E (pt) * 2006-02-15 2015-11-25 Adiutide Pharmaceuticals Gmbh Composições e métodos para formulações de oligonucleótidos
JP5437797B2 (ja) 2006-06-12 2014-03-12 サイトス バイオテクノロジー アーゲー Ｒｎａバクテリオファージのウイルス様粒子にオリゴヌクレオチドをパッケージ化するための方法
CN101517082B (zh) * 2006-09-27 2014-01-22 科勒制药有限责任公司 具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
MX2009007944A (es) * 2007-01-26 2009-08-07 Irm Llc Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
JP5346923B2 (ja) * 2007-05-04 2013-11-20 インデックス・ファーマシューティカルズ・アクチエボラーグ 腫瘍増殖阻害化合物及びそれらの使用方法
EP2167662A2 (en) * 2007-05-14 2010-03-31 Technische Universität München Pharmaceutical compounds comprising abasic oligonucleotides
PT2170353E (pt) * 2007-05-18 2015-09-16 Adiutide Pharmaceuticals Gmbh Análogos de oligonucleotídeo modificados por fosfato com atividade imunoestimulante
EP2190440A1 (en) * 2007-08-13 2010-06-02 Pfizer Inc. Combination motif immune stimulatory oligonucleotides with improved activity
KR20100068422A (ko) * 2007-10-09 2010-06-23 콜리 파마슈티칼 게엠베하 변경된 당 잔기를 함유하는 면역자극성 올리고뉴클레오티드 유사체
CN101932707B (zh) * 2008-01-31 2013-08-21 库瑞瓦格有限责任公司 作为免疫刺激剂/佐剂的式(I)(NuGlXmGnNv)a的核酸及其衍生物
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
WO2010067262A1 (en) * 2008-12-09 2010-06-17 Pfizer Inc. Immunostimulatory oligonucleotides
AU2010229835B2 (en) 2009-03-25 2015-01-15 The Board Of Regents Of The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
EP3165234B1 (de) * 2009-07-31 2019-04-03 ethris GmbH Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression
CN102905728B (zh) 2010-05-26 2015-11-25 西莱克塔生物科技公司 具有不偶合的佐剂的纳米载体组合物
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
EP2640190A4 (en) 2010-11-05 2016-05-11 Selecta Biosciences Inc MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
GB201021867D0 (en) 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
US20130028857A1 (en) 2011-07-29 2013-01-31 Selecta Biosciences, Inc. Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents
JP6129844B2 (ja) 2011-09-14 2017-05-17 ラナ セラピューティクス インコーポレイテッド 多量体オリゴヌクレオチド化合物
EP2809807B1 (en) * 2012-02-01 2019-04-10 Gen-Probe Incorporated Asymmetric hairpin target capture oligomers
KR20150030205A (ko) 2012-05-16 2015-03-19 라나 테라퓨틱스, 인크. Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
AU2013262709A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
JP2015523853A (ja) 2012-05-16 2015-08-20 ラナ セラピューティクス インコーポレイテッド Ａｔｐ２ａ２発現を調節するための組成物及び方法
SG11201407486PA (en) 2012-05-16 2014-12-30 Rana Therapeutics Inc Compositions and methods for modulating utrn expression
EA201492121A1 (ru) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии семейства генов гемоглобина
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
CN112007045B (zh) 2012-07-13 2026-01-06 波涛生命科学有限公司 手性控制
JP6246121B2 (ja) 2012-07-13 2017-12-13 株式会社新日本科学 キラル核酸アジュバント
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
CA2884608C (en) 2012-09-14 2025-05-20 Translate Bio Ma, Inc. MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
CN103233011B (zh) * 2013-04-22 2014-11-05 中国科学技术大学 PEG-PLA纳米材料包被的HBV-CpG在乙肝预防和/或治疗中的应用
WO2015024992A2 (en) * 2013-08-22 2015-02-26 Cytos Biotechnology Ag Treatment of asthma
CN105936906B (zh) * 2013-11-08 2019-06-21 上海交通大学 被修饰的含CpG序列单元的寡聚脱氧核苷酸分子及其用途
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10322173B2 (en) 2014-01-15 2019-06-18 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
KR102423317B1 (ko) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 키랄 디자인
GB2523187A (en) 2014-02-18 2015-08-19 Mologen Ag Covalently closed non-coding immunomodulatory DNA construct
EP3164113B1 (en) 2014-06-04 2019-03-27 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
US10858650B2 (en) 2014-10-30 2020-12-08 The General Hospital Corporation Methods for modulating ATRX-dependent gene repression
WO2016130943A1 (en) 2015-02-13 2016-08-18 Rana Therapeutics, Inc. Hybrid oligonucleotides and uses thereof
WO2016149455A2 (en) 2015-03-17 2016-09-22 The General Hospital Corporation The rna interactome of polycomb repressive complex 1 (prc1)
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
SG10202008046UA (en) 2015-12-23 2020-09-29 Univ Queensland Technology Nucleic acid oligomers and uses therefor
JP7186094B2 (ja) 2016-05-06 2022-12-08 イグジキュア オペレーティング カンパニー インターロイキン１７受容体ｍＲＮＡの特異的ノックダウンのためのアンチセンスオリゴヌクレオチド（ＡＳＯ）を提示するリポソーム系球状核酸（ＳＮＡ）構築物
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
EP3690030A4 (en) 2017-09-28 2021-06-23 Industry-Academic Cooperation Foundation, Yonsei University METHOD FOR MANUFACTURING MYELOID-DERIVED SUPPRESSOR CELLS, SUPPRESSOR CELLS MANUFACTURED FROM MYEOLID AND USES THEREOF
CN111801419A (zh) * 2017-12-15 2020-10-20 拜耳动物保健有限责任公司 免疫刺激性寡核苷酸
CN115154597A (zh) * 2022-06-28 2022-10-11 清华大学 一种新型疫苗佐剂及其用途

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5194428A (en) * 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5004810A (en) * 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
FI946201A0 (fi) 1992-07-02 1994-12-30 Hybridon Inc Itsestabiloidut oligonukleotidit terapeuttisina aineina
IL107150A0 (en) 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
US5646126A (en) 1994-02-28 1997-07-08 Epoch Pharmaceuticals Sterol modified oligonucleotide duplexes having anticancer activity
US6727230B1 (en) * 1994-03-25 2004-04-27 Coley Pharmaceutical Group, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
WO1995026204A1 (en) * 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
US5696248A (en) 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
US7935675B1 (en) * 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1996002555A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030050263A1 (en) * 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
JP4111403B2 (ja) * 1996-10-11 2008-07-02 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 免疫刺激ポリヌクレオチド／免疫調節分子複合体
AU7890598A (en) 1996-12-27 1998-07-31 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrimidine compounds and medicinal use thereof
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
WO1998037919A1 (en) * 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
US5939421A (en) 1997-07-01 1999-08-17 Signal Pharmaceuticals, Inc. Quinazoline analogs and related compounds and methods for treating inflammatory conditions
US6221882B1 (en) * 1997-07-03 2001-04-24 University Of Iowa Research Foundation Methods for inhibiting immunostimulatory DNA associated responses
US6218371B1 (en) * 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
CA2328602A1 (en) 1998-05-06 1999-11-11 University Of Iowa Research Foundation Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
WO1999058118A2 (en) 1998-05-14 1999-11-18 Cpg Immunopharmaceuticals Gmbh METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
DK1733735T3 (en) 1998-05-22 2017-06-19 Ottawa Hospital Res Inst Methods and products for the induction of mucosal immunity
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
WO2000006588A1 (en) 1998-07-27 2000-02-10 University Of Iowa Research Foundation STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
EP1108017A2 (en) 1998-09-03 2001-06-20 Coley Pharmaceutical GmbH G-motif oligonucleotides and uses thereof
WO2000015645A1 (fr) 1998-09-11 2000-03-23 Kyorin Pharmaceutical Co., Ltd. Derives d'esters phosphoniques et leur procede de production
US6207819B1 (en) * 1999-02-12 2001-03-27 Isis Pharmaceuticals, Inc. Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
WO2000054803A2 (en) * 1999-03-16 2000-09-21 Panacea Pharmaceuticals, Llc Immunostimulatory nucleic acids and antigens
AU4343700A (en) 1999-04-12 2000-11-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Oligodeoxynucleotide and its use to induce an immune response
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
ATE275727T1 (de) 1999-04-29 2004-09-15 Coley Pharm Gmbh Screening nach modulatoren der funktion von immunstimulatorischer dna
EP1377554A1 (en) 1999-06-16 2004-01-07 University Of Iowa Research Foundation Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
EP2314693A3 (en) 1999-08-13 2012-11-28 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
IL148843A0 (en) * 1999-09-25 2002-09-12 Univ Iowa Res Found Immunostimulatory nucleic acids
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
EP1322655B1 (en) * 2000-01-14 2007-11-14 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Oligodeoxynucleotide and its use to induce an immune response
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
EP1252307B1 (en) 2000-01-26 2008-01-02 Idera Pharmaceuticals, Inc. MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
US6887580B2 (en) * 2000-02-01 2005-05-03 Nippon Steel Chemical Co., Ltd. Adhesive polyimide resin and adhesive laminate
US7585847B2 (en) 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
WO2001062207A2 (en) 2000-02-23 2001-08-30 The Regents Of The University Of California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20040131628A1 (en) 2000-03-08 2004-07-08 Bratzler Robert L. Nucleic acids for the treatment of disorders associated with microorganisms
JP2003531915A (ja) 2000-05-01 2003-10-28 ハイブリドン・インコーポレイテッド ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ誘導性免疫刺激の調節
WO2001085751A1 (en) 2000-05-09 2001-11-15 Reliable Biopharmaceutical, Inc. Polymeric compounds useful as prodrugs
WO2001097843A2 (en) * 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
US20020165178A1 (en) 2000-06-28 2002-11-07 Christian Schetter Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
US20020198165A1 (en) 2000-08-01 2002-12-26 Bratzler Robert L. Nucleic acids for the prevention and treatment of gastric ulcers
US20020091097A1 (en) 2000-09-07 2002-07-11 Bratzler Robert L. Nucleic acids for the prevention and treatment of sexually transmitted diseases
JP2005500806A (ja) 2000-09-15 2005-01-13 コーリー ファーマシューティカル ゲーエムベーハー ＣｐＧに基づく免疫アゴニスト／免疫アンタゴニストの高スループットスクリーニングのためのプロセス
ATE384072T1 (de) 2000-09-26 2008-02-15 Idera Pharmaceuticals Inc Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
HU229642B1 (en) 2000-10-18 2014-03-28 Glaxosmithkline Beecham Biolog S A Vaccines against cancers
ES2307568T3 (es) 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
WO2002053141A2 (en) 2000-12-14 2002-07-11 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US7176296B2 (en) * 2001-04-30 2007-02-13 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
US7785610B2 (en) 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
US20040132677A1 (en) 2001-06-21 2004-07-08 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same-IV
EP1404873B1 (en) 2001-06-21 2013-05-22 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
US20030003970A1 (en) * 2001-06-28 2003-01-02 Alan Johnson Portable communications device
AU2002318944A1 (en) 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
WO2003020884A2 (en) * 2001-08-14 2003-03-13 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Method for rapid generation of mature dendritic cells
ES2314099T3 (es) * 2001-08-17 2009-03-16 Coley Pharmaceutical Gmbh Oligonucleotidos inmunoestimulantes con motivos combinados con actividad mejorada.
US20030067902A1 (en) * 2001-09-21 2003-04-10 Skeba Kirk W. Method for providing multiple certified radio modules with a baseband
EP1451581A4 (en) 2001-10-05 2006-01-11 Coley Pharm Gmbh AGONISTS AND ANTAGONISTS OF THE SIGNALING OF THE GREAT-SIMILAR RECEPTOR 3
EP1478371A4 (en) 2001-10-12 2007-11-07 Univ Iowa Res Found METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS
RU2185819C1 (ru) 2001-10-18 2002-07-27 Дорофеенко Алла Ивановна Средство, обладающее противоопухолевым действием
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US20030232443A1 (en) 2002-06-18 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of centromere protein B expression
CA2480775C (en) 2002-04-04 2016-05-31 Coley Pharmaceutical Gmbh Immunostimulatory g,u-containing oligoribonucleotides
SI2264172T1 (sl) 2002-04-05 2017-12-29 Roche Innovation Center Copenhagen A/S Oligomerne spojine za modulacijo izražanja HIF-1alfa
US20040009949A1 (en) * 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AU2003255969A1 (en) 2002-07-17 2004-02-02 Coley Pharmaceutical Gmbh Use of cpg nucleic acids in prion-disease
CN1468957A (zh) 2002-07-19 2004-01-21 中国人民解放军第二军医大学 一种用作人用治疗性疫苗佐剂的质粒
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
AU2003278845A1 (en) 2002-09-19 2004-04-08 Coley Pharmaceutical Gmbh Toll-like receptor 9 (tlr9) from various mammalian species
CA2503693A1 (en) 2002-10-29 2004-05-13 Coley Pharmaceutical Group, Ltd. Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
JP2006512927A (ja) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
US7625872B2 (en) 2002-12-23 2009-12-01 Dynavax Technologies Corporation Branched immunomodulatory compounds and methods of using the same
AU2004206820B2 (en) * 2003-01-16 2010-06-10 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
EP1608403A2 (en) * 2003-04-02 2005-12-28 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations for topical application
WO2004094671A2 (en) * 2003-04-22 2004-11-04 Coley Pharmaceutical Gmbh Methods and products for identification and assessment of tlr ligands
MXPA05013658A (es) * 2003-06-11 2006-03-02 Hybridon Inc Oligonucleotidos inmunomoduladores estabilizados.
JP2007524615A (ja) 2003-06-20 2007-08-30 コーリー ファーマシューティカル ゲーエムベーハー 低分子トール様レセプター（ｔｌｒ）アンタゴニスト
AU2004275876B2 (en) 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
US20050215501A1 (en) 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
CN101454451A (zh) 2003-10-30 2009-06-10 科勒制药有限公司 具有增强免疫刺激能力的c类寡核苷酸类似物
US20050239733A1 (en) 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) * 2003-11-06 2005-05-12 Coley Pharmaceutical Gmbh Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
AU2004304770B2 (en) 2003-12-08 2010-05-06 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties by small oligonucleotide-based compounds
EP1720568A2 (en) 2004-02-19 2006-11-15 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
AU2005243250A1 (en) * 2004-04-02 2005-11-24 Coley Pharmaceutical Gmbh Immunostimulatory nucleic acids for inducing IL-10 responses
CA2567789A1 (en) * 2004-06-08 2006-08-03 Coley Pharmaceutical Gmbh Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
EE200700003A (et) 2004-06-15 2007-06-15 Idera Pharmaceuticals, Inc. Immunostimuleeriv oligonukleotiid ning selle kasutamine
US7427405B2 (en) * 2004-06-15 2008-09-23 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
AU2005333126A1 (en) * 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing innate immune responses
CA2572427A1 (en) 2004-07-18 2006-01-18 Heather L. Davis Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
AU2006216493A1 (en) * 2005-02-24 2006-08-31 Coley Pharmaceutical Gmbh Immunostimulatory oligonucleotides
EP1874325A2 (en) 2005-04-08 2008-01-09 Coley Pharmaceutical Group, Inc. Methods for treating infectious disease exacerbated asthma
EP1899467A2 (en) 2005-04-26 2008-03-19 Coley Pharmaceutical GmbH Modified oligoribonucleotide analogs with enhances immunostimulatory activity
CN101268101A (zh) * 2005-07-07 2008-09-17 科利制药集团公司 用于癌症治疗的抗-CTLA-4抗体和含有CpG基序的合成寡脱氧核苷酸联合治疗
WO2007031877A2 (en) 2005-09-16 2007-03-22 Coley Pharmaceutical Gmbh Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification
EA013468B1 (ru) 2005-09-16 2010-04-30 Коли Фармасьютикал Гмбх Иммуностимулирующая одноцепочечная рибонуклеиновая кислота с фосфодиэфирным остовом
ES2536103T3 (es) 2005-11-25 2015-05-20 Zoetis Belgium S.A. Oligorribonucleótidos inmunoestimuladores
PT1991678E (pt) * 2006-02-15 2015-11-25 Adiutide Pharmaceuticals Gmbh Composições e métodos para formulações de oligonucleótidos
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
WO2008033432A2 (en) 2006-09-12 2008-03-20 Coley Pharmaceutical Group, Inc. Immune modulation by chemically modified ribonucleosides and oligoribonucleotides
CN101517082B (zh) 2006-09-27 2014-01-22 科勒制药有限责任公司 具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
CA2664156A1 (en) 2006-09-27 2008-04-03 Coley Pharmaceutical Group, Inc. Compositions of tlr ligands and antivirals
RU2009115687A (ru) 2006-10-26 2010-11-10 Коли Фармасьютикал Гмбх (De) Олигорибонуклеотиды и их применения
WO2008057529A2 (en) 2006-11-06 2008-05-15 Coley Pharmaceutical Group, Inc. Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp)
AU2008252577A1 (en) 2007-05-17 2008-11-27 Coley Pharmaceutical Gmbh Class A oligonucleotides with immunostimulatory potency

Also Published As

Publication number Publication date
AU2004285561A1 (en) 2005-05-12
AU2006201495A1 (en) 2006-04-27
US8188254B2 (en) 2012-05-29
GEP20094767B (en) 2009-09-10
EP1728863A3 (en) 2006-12-20
AU2004285561B2 (en) 2011-11-24
EA200600865A1 (ru) 2006-10-27
AU2004285561C1 (en) 2012-06-21
UA88457C2 (ru) 2009-10-26
WO2005042018A2 (en) 2005-05-12
US20050239734A1 (en) 2005-10-27
NZ546275A (en) 2009-05-31
TNSN06123A1 (en) 2007-11-15
SG122973A1 (en) 2006-06-29
JP2007509983A (ja) 2007-04-19
ECSP066589A (es) 2006-10-17
MA28182A1 (fr) 2006-09-01
NO20061857L (no) 2006-07-31
CN101454451A (zh) 2009-06-10
NZ546475A (en) 2008-08-29
WO2005042018A3 (en) 2005-07-21
CA2540949A1 (en) 2005-05-12
CR8423A (es) 2007-09-03
EP1678303A2 (en) 2006-07-12
KR101107818B1 (ko) 2012-01-31
ZA200603212B (en) 2008-03-26
OA13278A (en) 2007-01-31
KR20060109443A (ko) 2006-10-20
EP1728863A2 (en) 2006-12-06
SG123799A1 (en) 2006-07-26
EA008741B1 (ru) 2007-08-31
ZA200602352B (en) 2007-09-26
IL174428A0 (en) 2006-08-01
AP2006003611A0 (en) 2006-06-30
IL175215A0 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
TNSN06123A1 (en) C-class oligonucleotide analogs with enhaced immunostimulatory potency
BRPI0622298A8 (pt) Oligorribonucleotídeo para estimular a produção de uma citocina pró-inflamatória, uso do mesmo e composição contendo tal oligorribonucleotídeo
NO20061912L (no) Vaksinesammensetninger omfattende et interleukin 18 og saponin adjuvant system
BR0010612A (pt) Vacinas
BR0116470A (pt) éteres de imidazoquinolina substituìdos com uréia
MY137619A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
GT199900131A (es) Derivados del acido hidroxi-pipecolato hidroxamico.
UY31280A1 (es) Oligonucleotidos inmunoestimuladores con un motivo de combinacion con actividad mejorada
PE20061045A1 (es) OLIGONUCLEOTIDOS CpG INMUNOESTIMULADORES DE CLASE C
HUP0303720A2 (hu) Egy immunstimuláns oligonukleotidot és egy tokolt tartalmazó adjuvánskészítmény
GT200200053A (es) Derivados espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7
BRPI0511776A (pt) vìrus atenuado de influenza de suìnos, formulação imunogênica, formulação farmacêutica, métodos para imunizar ou induzir uma resposta imune em um porco, para tratar uma infecção por vìrus de influenza de suìnos em um porco, para tratar cáncer em um porco, e para produzir uma formulação imunogênica, célula, linhagem de células de porco, e, ovo embrionado
NO20061911L (no) Immunogene sammensetninger
BR0314373A (pt) Produto imunogênico estável para a indução de anticorpos contra uma ou várias proteìnas antigênicas em um indivìduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
GB2386072A (en) Novel vaccine
EP3676250A1 (en) Peptide conjugates, conjugation process, and uses thereof
DK0777669T3 (da) 4-[2-amino-6-(cyclopropylamino)-9H-purin-yl]-2-cyclopenten-1-methanolsuccinat som antiviralt middel
PA8590801A1 (es) Derivados de nucleosido antivirales
AR040242A1 (es) Composiciones farmaceuticas
IT1307786B1 (it) Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali.
BR0307121A (pt) antìgeno de superfìcie do vìrus da hepatite b como um imunoestimulador da mucosa e as formulações resultantes
BR0208980A (pt) Vacinas incluindo ifn do tipo i como um adjuvante e processos relacionados a esses
UY27372A1 (es) Derivados de bencimidazol 1-aril-2-n, s u o-sustituidos, su uso para la obtención de medicamentos y preparados farmacéuticos que contienen estos derivados
ES2140402T3 (es) Inhibidor nuclear i-92 y su uso para la produccion de un medicamento.
ATE342906T1 (de) Tumorhemmende cerverbindungen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2278 DE 02/09/2014.